042520 — HANS BIOMED Balance Sheet
0.000.00%
- KR₩95bn
- KR₩126bn
- KR₩81bn
- 23
- 34
- 33
- 17
Annual balance sheet for HANS BIOMED, fiscal year end - September 30th, KRW millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 22,862 | 20,268 | 13,553 | 7,048 | 7,259 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 15,526 | 9,983 | 10,529 | 13,114 | 12,138 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 58,696 | 51,113 | 54,371 | 50,393 | 49,707 |
Net Property, Plant And Equipment | 47,247 | 46,591 | 46,934 | 44,234 | 43,523 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 131,806 | 129,445 | 131,686 | 122,368 | 121,715 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 28,092 | 60,991 | 74,443 | 65,253 | 50,092 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 71,470 | 84,994 | 86,052 | 73,239 | 54,841 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 60,336 | 44,451 | 45,634 | 49,129 | 66,874 |
Total Liabilities & Shareholders' Equity | 131,806 | 129,445 | 131,686 | 122,368 | 121,715 |
Total Common Shares Outstanding |